linjc16/ctgov huggingface dataset:
Validation of an Allergic Rhinitis Control Test in Teenagers

Study Overview
=================
Brief Summary
-----------------
Allergic rhinitis is a common condition that affects adults as well as children and adolescents, often with impaired quality of life. Patients often report a poor level of satisfaction with the effectiveness of their treatment and are always looking for more drug combinations to improve their symptom. Several tools exist for assessing control of allergic rhinitis, but none has been validated in adolescents or in children. A study conducted in 2008, resulted in the validation of a self-administered control test of allergic rhinitsis (ARCT) in patients from 12 years of age. However, this study included only 67 adolescents aged 12 to 17 years old and lacked power. In this new study,the investigators propose, following exactly the same procedure as the pilot study of 2008, to confirme the validation of unmodified Adult questionnaire in adolescents 12 to 17 years inclusive.

Official Title
-----------------
Validation of an Allergic Rhinitis Control Test in Teenagers

Conditions
-----------------
Allergic Rhinitis

Intervention / Treatment
-----------------
* Other: Self questionnaire for allergic rhinitis control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 12 to 17 years old, consulting a practitioner for an allergic rhinitis parents formulated their study participation agreement by signing the consent form. Exclusion Criteria: Patients that are already treated for the actual episode of allergic rhinitis and are satisfied of the treatement.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: questionnaire for allergic rhinitis control<br>Teenagers from 12 to 17 years old who complete a Self questionnaire regarding allergic rhinitis control during the consultation and after 15 days | Other: Self questionnaire for allergic rhinitis control<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score of the allergic rhinitis control self questionnaire in teenagers from 12 to 17 years old. |  | 15 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allergic rhinitis
Risk Factors of Primary Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
Fibromyalgia (FM) is a condition with a different non-specific symptoms which lead to a difficult diagnosis. Study suggests that osteopathy can help in improving FM symptoms, nevertheless, it can be difficult to identify which patients may benefit. The knowledge of FM risk factor can be useful tool for osteopaths and other clinician to implement a targeted, fast and multidisciplinary treatment protocol for those kind of patient.

Official Title
-----------------
Risk Factors Recognition of Primary Fibromyalgia: a Case-control Study

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Other: Life Stressor Checklist Revised (LSC-R) (Appendix 1)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female patients Patient from Piedmont age between 20 and 65 years old inform consent for case group primary or secondary fibromyalgia Exclusion Criteria: systemic or rheumatic or neoplastic diseases for control group the presence of primary or secondary fibromyalgia
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Fibromyalgia<br>FM group was recruited at AMaR (rheumatic patients association of Piedmont) and the diagnosis of primary fibromyalgia was confirmed by the referring rheumatologist of the AMaR association. | Other: Life Stressor Checklist Revised (LSC-R) (Appendix 1)<br>* Evaluation of stress factor as risk factor for fibromyalgia development<br>|
| Control<br>The control group was recruited in the same geographic area as the FM participant. The general practitioner of each individual patient certified the subject's state of good health. | Other: Life Stressor Checklist Revised (LSC-R) (Appendix 1)<br>* Evaluation of stress factor as risk factor for fibromyalgia development<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of 29 stressing events | The LSC-R questionnaire was used to evaluate the incidence of each stressor event | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteopathy
Genomic Changes in Childhood Acute Lymphoblastic Leukemia

Study Overview
=================
Brief Summary
-----------------
To study the genomics with cell cycle and lymphocyte differentiation in disease, remission and relapse of childhood acute lymphoblastic leukemia. Then correlate these data with age, white cell count, cytogenetic changes, response to the chemotherapy and prognosis.

Detailed Description
-----------------
In order to know the genomic evolution of childhood acute lymphoblastic leukemia, we will collect bone marrow (10c.c.) at diagnosis, remission and relapse. We will do the following genes in addition to gene-chip including IKZF1,ETV6, EBF1, NR3C1, RAG1/G2, TCF3, BTLA, PAX5,LEF1, ERG and VPREB1.We will study the gene dosages and degree of methylation. The estimated patients numbers will be 300-400. Then we will correlate these data with patients'age, white blood cell count at diagnosis, cytogenetic abnormalities, response to the chemotherapy and prognosis.

Official Title
-----------------
Genomics Evolution in Childhood Acute Lymphoblastic Leukemia

Conditions
-----------------
Acute Lymphoblastic Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed as acute lymphoblastic leukemia age less than or equal to 18 years old signed informed consent Exclusion Criteria: who is not acute lymphoblastic leukemia who did not sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
genomic, childhood, acute lymphoblastic leukemia
The Use of Alternative Medicine by Palliative Care Patients

Study Overview
=================
Brief Summary
-----------------
Palliative care centres in Lyon, France as well as the disclosure of Complementary and Alternative Medicine and conventional healthcare use to conventional and Complementary and Alternative Medicine practitioners respectively. These aims will be achieved through the following objectives: Describe the prevalence of Complementary and Alternative Medicine practitioner and product use in the outpatient population of palliative care centres in Lyon, France Describe the characteristics of Complementary and Alternative Medicine users the outpatient population of palliative care centres in Lyon, France Estimate the Complementary and Alternative Medicine expenditure of the outpatient population of palliative care centres in Lyon, France Describe the rates of disclosure of both Complementary and Alternative Medicine and conventional health care to health professionals by the outpatient population of palliative care centres in Lyon, France Describe the reasons for disclosure or non-disclosure of both Complementary and Alternative Medicine and conventional health care to health professionals by the outpatient population of palliative care centres in Lyon, France

Official Title
-----------------
The Use of Complementary Medicine in Palliative/Supportive Care Centres in Lyon, France

Conditions
-----------------
Cancer, Terminal Cancer

Intervention / Treatment
-----------------
* Other: Complementary medicine use


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients accessing care from a palliative/supportive care centre in Lyon, France Can read and understand French Has been diagnosed with cancer Exclusion Criteria: The primary health condition for which they are attending the centre is not cancer They are not able to read and understand French

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Palliative/Supportive care<br>Individuals with cancer receiving palliative or supportive care | Other: Complementary medicine use<br>* The prevalence of complementary medicine use<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complementary medicine use | The prevalence of complementary medicine use. Data collected using a questionnaire. | 15 minutes |
Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study

Study Overview
=================
Brief Summary
-----------------
This is a phase II, single center, open-label, non randomized clinical study to assess the uptake, safety and tolerability of Imatinib in acute Cervical Spinal Cord Injury patients. The aim is to determine if Imatinib reaches sufficient blood levels when given to patients with cervical spinal cord injury, via a gastric feeding tube, and also evaluate the safety and tolerability of this drug treatment.

Official Title
-----------------
Treatment of Acute Cervical Spinal Cord Injury With Imatinib (Glivec®) - a Safety and Feasibility Study (EudraCT no 2014-002170-36)

Conditions
-----------------
Cervical Spinal Cord Injury

Intervention / Treatment
-----------------
* Drug: Imatinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women aged 18-80 years Clinical signs of cervical spinal cord injury due to trauma. In otherwise good health condition as determined by past medical history, physical examination, laboratory tests and vital signs Patient that is conscious and oriented x 4 (regarding date/time, localisation, situation and personal details), with higher level of consciousness, i.e. Glasgow Coma Scale > 14, and is assessed to be competent to give informed consent. Exclusion Criteria: Diabetes (type I and II) Ongoing cancer treatment Known allergy to study drug Imatinib or its excipients On current therapy with drugs which may interfere with Imatinib, (e.g. paracetamol, ketoconazole, itraconazole, erythromycin, clarithromycin, dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital, fosphenytoin, primidon, Hypericum perforatum). Female subjects lactating or with positive pregnancy test Known liver or kidney disease Any relevant surgical or medical condition which in the opinion of the investigator may interfere with the conduct of the study or the scientific results. This includes hemorrhagic conditions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Imatinib<br>Day 1. 800 mg, Day 2-14: 2 * 400 mg per day | Drug: Imatinib<br>* Day 1. 800 mg, Day 2-14: 2 * 400 mg per day<br>* Other names: Glivec;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in levels of Imatinib in plasma and cytokines in serum day 1-3, 7, 10, 14, 16, 19 |  | Day 1-3, 7, 10, 14, 16, 19 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events |  | Day 1-19 |
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia

Study Overview
=================
Brief Summary
-----------------
This study will collect data on safety, effectiveness and patient acceptance of MabCampath treatment under daily life conditions.

Detailed Description
-----------------
As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.

Official Title
-----------------
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia (CLL)

Conditions
-----------------
Chronic Lymphocytic Leukemia

Intervention / Treatment
-----------------
* Drug: Alemtuzumab (MabCampath)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In- and outpatients suffering from CLL, who are treated with Mab Campath, and are routinely monitored with PCR (Polymerase Chain Reaction) for CMV infection during MabCampath treatment and for at least 2 months following completion of treatment. Exclusion Criteria: In accordance with Summaries of Product Characteristics (SPC).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Alemtuzumab (MabCampath)<br>* Intravenous therapy according to product information.<br>* Other names: BAY86-5045;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy related variables are patient's condition, physician's assessment of efficacy and tolerability, information whether application could be completed, clinical and laboratory findings. Safety Variables. |  | After first cycle of treatment, e.g. 12 weeks, then after 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
alemtuzumab, CLL
Environmental Intervention to Reduce Allergens in Urban Schools and Childhood Asthma

Study Overview
=================
Brief Summary
-----------------
The investigators aim to pilot the role of school based intervention consisting of enhanced integrated pest management, classroom air purifiers and cleaning improves asthma morbidity.

Detailed Description
-----------------
By piloting this school based intervention, the investigators hope to learn from this study the best way to design and implement more cost and time efficient large-based school-based environmental interventions that may potentially help a community of children with asthma, allergic diseases, and its associated morbidity.

Official Title
-----------------
Environmental Intervention to Reduce Allergens in Urban Schools and Childhood Asthma

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Other: integrated pest management
* Other: air purifier
* Other: Sham air purifier


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: grades K-8 with asthma attending sampling/intervention schools Exclusion Criteria: moving schools

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Environmental Intervention<br>4 classroom air purifiers and school integrated pest management environmental intervention | Other: integrated pest management<br>* integrated pest management and environmental strategy<br>Other: air purifier<br>* air purifiers<br>|
| Placebo Comparator: Sham and Control<br>4 sham air purifiers and no school integrated pest management environmental intervention | Other: Sham air purifier<br>* sham air purifiers<br>|
| Placebo Comparator: Active Air Purifier and Control<br>4 air purifiers and no school integrated pest management environmental intervention | Other: air purifier<br>* air purifiers<br>|
| Sham Comparator: Sham and Integrated Pest Management<br>4 classroom sham air purifiers and school integrated pest management | Other: integrated pest management<br>* integrated pest management and environmental strategy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Asthma Symptoms | number of days of wheezing/cough | over a two week period at Baseline and Months 3, 6, 9 and 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung Function | peak expiratory flow (PEF) | measured at baseline and months 6 and 12 |
Train-of-four Monitoring Using the Tetragraph

Study Overview
=================
Brief Summary
-----------------
This is a prospective study that will evaluate the feasibility of using the Tetragraph Neuromuscular Transmission Monitor in comparison to standard (visual) train-of-four assessment with a peripheral nerve stimulator in pediatric patients undergoing surgery.

Official Title
-----------------
Train-of-four Monitoring Using the Tetragraph Neuromuscular Transmission Monitor and Comparison to Standard (Visual) Train-of-four Assessment With a Peripheral Nerve Stimulator

Conditions
-----------------
Surgery

Intervention / Treatment
-----------------
* Device: Tetragraph (TM) NMT Monitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric patients requiring anesthetic care and use of neuromuscular blockade Weight range of 20 - 60 kg Exclusion Criteria: Patients with history of a peripheral neurologic or neuropathic disorder Patients in whom the upper extremity cannot be used for TOF monitoring Patients undergoing a surgical procedure in which neuromuscular blockade is not required Edematous patients

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tetragraph<br> | Device: Tetragraph (TM) NMT Monitor<br>* TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EMG changes | Changes in the amplitude of the evoked response of the muscles. | During the surgery |
Swiss National Iodine Survey 2020

Study Overview
=================
Brief Summary
-----------------
This study will assess iodine status in school aged children and pregnant women is Switzerland. In addition, thyroid status and omega-3 index will be assessed in pregnant women.

Official Title
-----------------
Swiss National Iodine Survey 2020

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: There is no intervention. It is an observational study.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy for pregnant women: confirmed pregnancy living in Switzerland for min 1 year Exclusion Criteria: no history of major medical illness no iodine containing contrast agents or medication in the past 6 months

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| School aged children<br> | Other: There is no intervention. It is an observational study.<br>* There is not intervention<br>|
| Pregnant women<br> | Other: There is no intervention. It is an observational study.<br>* There is not intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary iodine concentration | urinary iodine concentration in spot urine samples | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urinary creatinine concentration | Urinary creatinine concentration in spot urine samples | Baseline | 
| Urinary sodium concentration | Urinary sodium concentration in spot urine samples | Baseline | 
| Urinary fluoride concentration | Urinary fluoride concentration in spot urine samples | Baseline | 
| Thyroid stimulating hormone | TSH from dried blood spots | Baseline | 
| T3 | T3 from dried blood spots | Baseline | 
| T4 | T4 from dried blood spots | Baseline | 
| Omega 3 index | Omega 3 index from dried blood spots | Baseline |